Copyright: ©Author(s) 2026.
World J Gastrointest Oncol. Sep 15, 2026; 18(9): 121282
Published online Sep 15, 2026. doi: 10.4251/wjgo.121282
Published online Sep 15, 2026. doi: 10.4251/wjgo.121282
Figure 3 The effect of cyclin-dependent kinase 6 on the migration of gastrointestinal stromal tumor cells.
T1 vs T1 + ripretinib (Ri), T1 + palbociclib (P) vs T1 + Ri + P (P < 0.001), 882 vs 882 + Ri, 882 + P vs 882 + Ri + P (P < 0.001), 430 vs 430 + Ri, 430 + P vs 430 + Ri + P (P < 0.001). T1 vs T1 + P, T1 + Ri vs T1 + Ri + P (P > 0.05), 882 vs 882 + P, 882 + Ri vs 882 + Ri + P (P > 0.05), 430 vs 430 + P, 430 + Ri vs 430 + Ri + P (P > 0.05). T1 resistance index (RI) vs T1RI + P, T1RI + Ri vs T1RI + Ri + P (P > 0.05), 882RI vs 882RI + P, 882RI + Ri vs 882RI + Ri + P (P > 0.05), 430RI vs 430RI + P, 430RI + Ri vs 430RI + Ri + P (P > 0.05). aP < 0.001. Scale bar = 100 μm. P: Palbociclib; Ri: Ripretinib; RI: Resistance index.
- Citation: Wang XD, Shou CH, Chen SC, Hong YY, Zhu KK, Yang WL, Yu JR. Targeting cyclin-dependent kinase 6 partially reverses drug resistance in ripretinib-resistant gastrointestinal stromal tumor cells in vitro. World J Gastrointest Oncol 2026; 18(9): 121282
- URL: https://www.wjgnet.com/1948-5204/full/v18/i9/121282.htm
- DOI: https://dx.doi.org/10.4251/wjgo.121282